Merck Presents New Data Examining Durable Efficacy with Investigational Cladribine Tablets in Multiple Sclerosis
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK-based media - Phase III studies highlight lasting reductions in relapse rates for an additional two years following short oral treatment courses in year one & year two with Cladribine Tablets Merck, a leading science and technology company, announced they ...